New Leadership at Editas Medicine: What it Means for the IRD Community
Cambridge, MA – The inherited retinal disease (IRD) community is closely watching developments at leading genome editing companies, as advancements in gene therapy hold significant promise for restoring vision. Editas Medicine, a company focused on translating CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into treatments, announced a key leadership change in April 2022 that could impact the future of IRD research and development.
Dr. Gilmore O’Neill was appointed President and Chief Executive Officer of Editas Medicine, effective June 1, 2022. This transition brought a leader with nearly two decades of experience in genetic medicine, neurobiology, and clinical development to the helm of a company actively exploring treatments for serious diseases. James C. Mullen, the previous CEO, transitioned to the role of Executive Chairman of the Board of Directors.
Dr. O'Neill's background includes serving as Executive Vice President of R&D and Chief Medical Officer at Sarepta Therapeutics, and holding various leadership roles at Biogen for 15 years. During his tenure at Biogen, he oversaw development programs for rare diseases, gene and cell therapy, and neuromuscular diseases, among others. He has a track record of driving clinical programs and achieving marketing approvals for several medicines, including Spinraza®, Amondys®, and Vyondys®.
For patients and families affected by IRDs, leadership changes at companies like Editas Medicine are important because they can influence strategic direction and resource allocation for gene therapy programs. Editas Medicine has been involved in IRD research, including its EDIT-101 program for Leber Congenital Amaurosis 10 (LCA10), which leverages the CRISPR/Cas9 system. In 2022, Editas Medicine released clinical trial data from the Phase 1/2 BRILLIANCE trial for EDIT-101, demonstrating that a CRISPR-based gene editing therapeutic could be safely delivered to the retina and achieve clinically meaningful outcomes. However, in January 2023, Editas Medicine announced a strategic reprioritization, discontinuing internal investments in its inherited retinal disease programs, including EDIT-101 and EDIT-103 for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). The company stated it would seek partnerships for the further development of its IRD programs.
Dr. O'Neill has expressed excitement about the potential of Editas' pipeline and its CRISPR-driven technology. While the company has shifted its internal focus away from IRD programs, the potential for future partnerships could still bring these therapies closer to patients. The experience of leaders like Dr. O'Neill in advancing drugs through clinical development and regulatory approval could be beneficial should new collaborations emerge for IRD treatments.
The IRD community remains hopeful that Editas Medicine's commitment to gene editing, combined with Dr. O'Neill's expertise, will eventually contribute to new therapeutic options for inherited retinal diseases through strategic collaborations.